Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
C2N Diagnostics logo — Fierce Medtech named C2N one of its Fierce 15 for 2020; "one...

C2N Diagnostics

Fierce Medtech named C2N one of its Fierce 15 for 2020; "one of the most promising private companies in the industry.”

Founded 2007 United States United States 92 employees Corporate Round Total: $52.20M Biotechnology

General Information

Company Name C2N Diagnostics
Founded Year 2007
Location United States United States +1
Employees 92
Industries Biotechnology
Funding Stage Corporate Round
Social

Get notified when C2N Diagnostics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About C2N Diagnostics

C2N Diagnostics, established in 2007 and headquartered in the United States, is a biotechnology startup making significant strides in the medical industry. The company's dedication to innovation and excellence has been acknowledged by Fierce Medtech, which named C2N one of its Fierce 15 for 2020, recognizing it as "one of the most promising private companies in the industry." C2N Diagnostics is committed to bringing Clarity Through Innovation™ to the forefront of therapeutic discovery and diagnostics for human neurological disorders. Its flagship product, the PrecivityAD™ blood test, employs mass spectrometry to measure multiple analytes in the blood, including Aβ42, Aβ40, and apolipoprotein E isoforms. While not a standalone diagnostic tool for Alzheimer's disease, it serves as a crucial aid for physicians in the evaluation process, predicting brain amyloid plaques as determined by PET scan results. Notably, the test has received a Breakthrough Device Designation from the U.S. Food and Drug Administration and has achieved the CE Mark from the European Union. C2N's steadfast commitment to advancing brain health monitoring through accessible and cost-effective blood tests has not gone unnoticed. In March 2024, the company secured a remarkable $15.00M corporate round investment from Eisai US, endorsing its pioneering efforts in revolutionizing neurological disorder diagnostics and therapeutic discovery. For further details, visit www.C2N.com.

Taxonomy: Medtech, Diagnostics, Therapeutic Discovery, Neurological Disorders, Blood Tests, Alzheimer’s Disease, Precision Medicine, Mass Spectrometry, Health Care, FDA Breakthrough Device, CE Mark, Protein Diagnostics, Neurodegeneration, Research and Development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Corporate Round •••••• 1 •••• •••• 06 Mar 2024
Venture Round •••••• 1
Investor
16 Feb 2023
Grant •••••• 1 •••• •••• 24 Sep 2020
Venture Round •••••• 1
Investor
15 May 2020

C2N Diagnostics Alternatives & Competitors

C2N Diagnostics vs
Hemosure®
Hemosure® United States

The #1 iFOB Test in the US.

25 employees
Food and Beverage, Manufacturing
Compare C2N Diagnostics vs Hemosure®
C2N Diagnostics vs
Cogniciti
Cogniciti Canada

Healthier brains. Stronger minds. Better lives.

2 employees
Biotechnology, Health Care
Compare C2N Diagnostics vs Cogniciti
C2N Diagnostics vs
PetDx
PetDx United States

The Liquid Biopsy Company for Pets ™

Series B
13 employees
Compare C2N Diagnostics vs PetDx

FAQ About C2N Diagnostics

Fierce Medtech named C2N one of its Fierce 15 for 2020; "one of the most promising private companies in the industry.”
C2N Diagnostics was founded in 2007.
C2N Diagnostics is headquartered in United States.
C2N Diagnostics operates in the following industries: Biotechnology.
C2N Diagnostics has approximately 92 employees.
C2N Diagnostics has completed 4 funding rounds, raising a total of $52.20M. The latest funding stage is Corporate Round.
Top alternatives and competitors to C2N Diagnostics include Hemosure®, Cogniciti, PetDx, Morepen Laboratories Limited India, Adela, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
C2N Diagnostics and Hemosure® are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors C2N Diagnostics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy